Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Down 29.6% in December

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) was the recipient of a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 1,570,000 shares, a decrease of 29.6% from the November 30th total of 2,230,000 shares. Based on an average trading volume of 8,330,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 9.0% of the shares of the stock are sold short.

Insider Activity

In other Syros Pharmaceuticals news, Director Nancy A. Simonian sold 134,713 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $0.27, for a total value of $36,372.51. Following the transaction, the director now directly owns 41,070 shares of the company’s stock, valued at $11,088.90. This trade represents a 76.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 12.26% of the company’s stock.

Institutional Investors Weigh In On Syros Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Exome Asset Management LLC increased its position in shares of Syros Pharmaceuticals by 87.6% during the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after buying an additional 139,400 shares during the period. Certuity LLC acquired a new stake in Syros Pharmaceuticals during the 2nd quarter worth about $109,000. Acadian Asset Management LLC increased its holdings in Syros Pharmaceuticals by 101.5% in the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after purchasing an additional 17,416 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of Syros Pharmaceuticals during the 3rd quarter worth approximately $34,000. Institutional investors and hedge funds own 91.47% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on SYRS shares. HC Wainwright restated a “neutral” rating and set a $1.00 price objective (down from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. StockNews.com assumed coverage on Syros Pharmaceuticals in a research report on Monday, December 23rd. They issued a “sell” rating on the stock. TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, JMP Securities reiterated a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, Syros Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Trading Down 3.2 %

Shares of Syros Pharmaceuticals stock traded down $0.01 on Friday, hitting $0.21. The stock had a trading volume of 5,146,148 shares, compared to its average volume of 2,356,837. The stock has a 50 day moving average of $0.99 and a 200 day moving average of $2.70. The firm has a market capitalization of $5.61 million, a P/E ratio of -0.07 and a beta of 1.33. Syros Pharmaceuticals has a twelve month low of $0.18 and a twelve month high of $8.17. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.25 and a current ratio of 2.25.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same quarter last year, the firm earned ($1.35) earnings per share. Sell-side analysts expect that Syros Pharmaceuticals will post -2.94 earnings per share for the current fiscal year.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.